Medicine

Admera Health Announces Appointment of Omar Karame as Chief Financial Officer

Tuesday, December 10, 2019 - 4:45pm

SOUTH PLAINFIELD, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Admera Health, a molecular diagnostics company, welcomes Omar Karame as Chief Financial Officer to the company.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Admera Health, a molecular diagnostics company, welcomes Omar Karame as Chief Financial Officer to the company.
  • Mr. Karame brings to Admera Health more than 20 years of finance and capital markets experience.
  • Admera Health is a leader in championing pharmacogenomics as a standard of quality patient care, stated Guanghui Hu, Ph.D., President, and CEO of Admera Health.
  • Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research services.

DaVinci Introduces IQ2 Premium Vaporizer with Original Load Your Own & Know Your Dose Technology

Tuesday, December 10, 2019 - 4:00pm

DaVinci , leading innovator and manufacturer of premium vaporizer devices, today announced the launch of the IQ2, a portable dual-use vaporizer with unprecedented dosage control technology that elevates cannabis consumption with a customized experience.

Key Points: 
  • DaVinci , leading innovator and manufacturer of premium vaporizer devices, today announced the launch of the IQ2, a portable dual-use vaporizer with unprecedented dosage control technology that elevates cannabis consumption with a customized experience.
  • As the first Load Your Own & Know Your Dose vaporizer, the IQ2 features full on-device dosage control and session-tracking information without requiring a separate app.
  • The IQ2 is a universal dual-use device, empowering consumers to load their own flower or extracts, regardless of brand, and track their cannabinoid consumption per draw and per session.
  • Since DaVincis founding, the team has established a legacy in creating trusted products such as the DaVinci Classic, the DAVINCI IQ and the IQ2.

Global Throat Pastilles and Cough Drops Market 2020-2024 | Evolving Opportunities With Kestrel Medical Ltd. and Pfizer Inc. | Technavio

Tuesday, December 10, 2019 - 4:30pm

The market is driven by the advantages of throat pastilles and cough drops over other dosage forms.

Key Points: 
  • The market is driven by the advantages of throat pastilles and cough drops over other dosage forms.
  • Also, the emergence of innovative products is anticipated to further boost the growth of the throat pastilles and cough drops market.
  • Thus, the advantages of throat pastilles and cough drops over other dosage forms is expected to drive market growth during the forecast period.
  • Kestrel Medical Ltd. is headquartered in the UK and offers Vocalzone as its vital offering for the throat pastilles and cough drops market.

Parkinson's Foundation Announces New Sites for Parkinson's Genetic Testing and Counseling

Tuesday, December 10, 2019 - 1:58pm

Genetic testing results obtained through this study will be used for future research by scientists to develop improved treatments and personalized medicine for Parkinson's disease (PD).

Key Points: 
  • Genetic testing results obtained through this study will be used for future research by scientists to develop improved treatments and personalized medicine for Parkinson's disease (PD).
  • Currently, genetic tests are either not available or not affordable for people with PD and frequently are not covered by health insurance or offered with genetic counseling.
  • After the pilot period, the Parkinson's Foundation hopes to expand the program to approximately 50 Centers of Excellence and Parkinson Study Group sites across the U.S. in 2020, ultimately offering genetic testing and genetic counseling for up to 15,000 people with PD.
  • The Parkinson's Foundation makes life better for people with Parkinson's disease by improving care and advancing research toward a cure.

India Aromatherapy Diffusers Market Report 2019 Featuring Aroma Diffusers, N. Ranga Rao & Sons, Renaissance Creations, Soulflower - ResearchAndMarkets.com

Tuesday, December 10, 2019 - 3:28pm

The "2019 India Aromatherapy Diffusers Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "2019 India Aromatherapy Diffusers Market" report has been added to ResearchAndMarkets.com's offering.
  • A comprehensive analysis of the Indian Aromatherapy Diffusers Market including market sizing, market share by competitor, driver restraints and forecasts to 2025
    Diffusion is the process of dispersing essential oils so that their aroma fills a room (or an area) with the natural fragrance.
  • For the purposes of this report, diffuser types include ultrasonic, nebulizer, evaporative, and heat (not including reed diffusers).
  • The report provides an overview of the Aromatherapy Diffuser Market in India.

Global Heart Valve Repair and Replacement Devices Market 2019-2023| Evolving Opportunities with Abbott and CryoLife, Inc | Technavio

Tuesday, December 10, 2019 - 4:00pm

View the full release here: https://www.businesswire.com/news/home/20191210005681/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191210005681/en/
    Technavio has announced its latest market research report titled global heart valve repair and replacement devices market 2019-2023 (Graphic: Business Wire)
    Read the 127-page research report with TOC on "Heart Valve Repair and Replacement Devices Market Analysis Report by Product (Heart valve replacement devices and Heart valve repair devices), by Surgery (Minimally invasive surgeries, Transcatheter surgeries, and Open surgeries), by Geography (Asia, Europe, North America, and ROW), and Segment Forecasts, 2019-2023".
  • Also, technological advances in heart valve repair and replacement devices are anticipated to further boost the growth of the market during the forecast period.
  • They offer heart valve repair and replacement surgeries to repair and replace defective heart valves that are prone to these conditions.
  • Heart Defect Closure Devices Market Global Heart Defect Closure Devices Market by product (LAA closure devices, PFO closure devices, ASD closure devices, and other heart defect closure devices) and geography (Asia, Europe, North America, and ROW).

Cardiac Rhythm Management Devices Market Size, Share & Trend Analysis Report By Product And Segment Forecasts, 2019 - 2026

Tuesday, December 10, 2019 - 1:20pm

Cardiac Rhythm Management Devices Market Size, Share & Trend Analysis Report By Product (Pacemaker, Defibrillators, & CRT Devices) And Segment Forecasts, 2019 - 2026

Key Points: 
  • Cardiac Rhythm Management Devices Market Size, Share & Trend Analysis Report By Product (Pacemaker, Defibrillators, & CRT Devices) And Segment Forecasts, 2019 - 2026
    The global cardiac rhythm management devices market size is anticipated to reach USD 32.7 billion by 2026, is expected to grow at a CAGR of 7.1% during the forecast period as per the new report.
  • The cardiac rhythm management (CRM) devices market has shown a constant growth in the adoption of CRM devices owing to the increasing prevalence of cardiovascular disorders.
  • Revolutionary technological progresses are rapidly transforming the cardiac rhythm management market.
  • The ICD segment was the largest sub segment in 2018, accounting for over 70.00% of the market share, owing to its better patient outcome.

Marijuana Company of America to Present at the 12th Annual LD Micro Main Event Held on December 10-12, 2019

Tuesday, December 10, 2019 - 1:07pm

ESCONDIDO, Calif., Dec. 10, 2019 /PRNewswire/ -- Marijuana Company of America, Inc. ("MCOA" or the "Company") (OTCQB: MCOA), an innovative hemp and cannabis corporation, today announced it will be presenting at the 12th Annual LD Micro Main Event held on December 10-12, 2019 at the Luxe Sunset Boulevard Hotel, in Bel Air, California.

Key Points: 
  • ESCONDIDO, Calif., Dec. 10, 2019 /PRNewswire/ -- Marijuana Company of America, Inc. ("MCOA" or the "Company") (OTCQB: MCOA), an innovative hemp and cannabis corporation, today announced it will be presenting at the 12th Annual LD Micro Main Event held on December 10-12, 2019 at the Luxe Sunset Boulevard Hotel, in Bel Air, California.
  • Mr. Jesus Quintero, Principal Executive Officer of the Company, and Mr. Robet Coale, Director of the Company, are scheduled to present on Wednesday, December 11, 2019 at 11:40 AM PT.
  • The presentation will cover a corporate overview, including recent highlights, the hempSMART brand, and current developments.
  • Mr. Coale and Mr. Quintero will also be available for 1x1 meetings with investors during the conference.

Vantage Hemp Co. Appoints Prominent Dr. Daniel Chinnapen as Chief Scientific Officer

Tuesday, December 10, 2019 - 2:15pm

GREELEY, Colo., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vantage Hemp Co., an emerging leader in science, innovation and technology in CBD extraction, is pleased to announce Dr. Daniel Chinnapen as its new Chief Scientific Officer.

Key Points: 
  • GREELEY, Colo., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Vantage Hemp Co., an emerging leader in science, innovation and technology in CBD extraction, is pleased to announce Dr. Daniel Chinnapen as its new Chief Scientific Officer.
  • I am eager to join Vantage Hemp and privileged to support the companys vision of purity through innovation, says Dr. Daniel Chinnapen, Chief Scientific Officer of Vantage Hemp.
  • The same applies to the addition of exceptional people like Dr. Daniel Chinnapen to the Vantage Hemp team.
  • With 800-acres of U.S. certified hemp biomass and large-scale, high volume extraction facilities, Colorado-based Vantage Hemp has CBD extraction down to a science.

Darzalex®▼ (daratumumab) Regimen Shows Significant Increase in Progression-Free Survival in Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Tuesday, December 10, 2019 - 2:13pm

This Phase 3 study adds to the body of evidence related to the use of daratumumab in combination with established regimens for the treatment of patients with relapsed multiple myeloma.

Key Points: 
  • This Phase 3 study adds to the body of evidence related to the use of daratumumab in combination with established regimens for the treatment of patients with relapsed multiple myeloma.
  • We are committed to the continued study of daratumumab as a treatment in patients with multiple myeloma.
  • This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the benefits of daratumumab for the treatment of patients with multiple myeloma.
  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.